Medis and Onkodatamed Link Up for Oncology Trials
Medis Research Group has been joined by ONKODATAMED GmbH in a bid to consolidate the group's position as an oncology trial specialist...
Medis Research Group, a strategic alliance of Berlin-based CROs, has been joined by another CRO from the Berlin area, ONKODATAMED GmbH, in a bid to consolidate the group’s position as an oncology trial specialist covering Germany, Austria and Switzerland.
Medis was founded in November 2013, and its two founding members were Allied Clinical Management and ICRC-Weyer. The group was formed in a move to better meet requirements of clinical trial sponsors for "one-stop shop solutions."
Onkodatamed is a specialist provider of remote data capture solutions within a network of dermatologic, urologic and gynecologic oncologists. Through this network, Medis now has access to one of the largest epidemiological and clinical oncology databases in Europe containing information on thousands of patients currently in treatment – a valuable source for retrospective data analysis.
“The group’s clinical research services complement the portfolio of Onkodatamed enabling us to jointly provide a wide range of services for the conduct of entire trial projects and retrospective data analysis. On the other hand, we can contribute to the group with our proven remote data capture software ODM QuaSi as well as our large database of urologic and gynecologic oncology patients,” said Dr. Lutz Reimer, Managing Director of Onkodatamed.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
